Reporte zur Charge UH714AA

Symptomtext

allergic reaction; Initial information regarding an unsolicited valid non-serious case was received from a other healthcare professional via Medical Information (Reference number- 00535257) and transmitted to Sanofi on 25-Mar-2021. This case involves a female patient (age not reported) who had allergic reaction (allergy to vaccine) while receiving INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE]. The patient's past vaccination(s) included Influenza vaccine in 1970 and DTP VACCINE for prophylactic vaccination and experienced itching after receiving DTP VACCINE. The patient's medical history, past medical treatment(s), concomitant medications and family history were not provided. On 20-Sep-2012, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE (lot UH714AA and expiry date: 30-Jun-2013) via an unknown route in an unknown administration site for prophylactic vaccination. On 20-Sep-2012 the patient developed a non-serious allergic reaction (allergy to vaccine) same day following the administration of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE. The caller had a known allergy to thimerosal. She had an allergic reaction to a flu vaccine but does not know which manufacturer's vaccine it was that caused the reaction. At the time, it was thought her allergic reaction happened due to her thimerosal allergy because even though the outer package of the vaccine she received indicated "thimerosal free", it was later found in the package insert that the product contained a millimicron of thimerosal. She did not have information about what presentation but thinks it was possible that it was from a single dose vial. She summarized that she had only reacted to two types of vaccines in her lifetime. She had reacted mildly with itching to DTP vaccines. She did not receive any more flu vaccines until in 2007 and at that time went into the hospital. She avoided reactions because that entire time she thought it was thimerosal she was allergic to, and as long as she would avoid thimerosal, she thought she was okay. But she did note that her allergist did not believe that thimerosal causes allergic reactions of the type that she experienced. The details of laboratory data were not reported. It was not reported if the patient received a corrective treatment for the event. At time of reporting, the outcome was unknown for the event.